周四盘中，诺瓦瓦克斯医药（NVAX）股价大跌5.02%，引发市场关注。这一跌势与美国食品和药物管理局（FDA）延迟批准该公司新冠疫苗的消息密切相关。
据报道，FDA要求诺瓦瓦克斯提供更多临床数据，以证明其新冠疫苗的有效性。这一决定可能影响了投资者对公司短期前景的信心。诺瓦瓦克斯的疫苗是美国唯一一种不使用mRNA技术的新冠加强针，对于不能或不愿接种mRNA疫苗的人群来说尤为重要。
尽管FDA的决定带来了挑战，但诺瓦瓦克斯表示，根据与FDA的沟通结果，公司认为其申请"可以批准"，只是需要在批准后提供更多数据。这一消息为公司股价未来反弹带来了一线希望。然而，由于现有批次的诺瓦瓦克斯疫苗将于4月30日到期，公司面临着时间压力。投资者将密切关注公司如何应对这一挑战，以及FDA的最终决定对公司长期发展的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.